Novel blood test for diagnosing Alzheimer’s disease at early stage

Berlin: Alzheimer’s disease can now be detected at an early stage, with the newly found blood test, which is based on immune- chemical analysis using an infrared sensor. The researchers have warned the people up to Fifteen years before the symptoms appear.

The sensor which is used o as referred above by the scientists, its surface is to be coated with the highly specific antibodies which extract biomarkers for Alzheimer’s from the blood or the cerebrospinal fluid, which are taken from the lower part of the back (lumbar liquor).

The Alzheimer’s disease which is a chronic neurodegenerative disease that usually starts slowly and gets worse over time and, gradually, bodily functions are lost, ultimately leading to death. And in its other risk factors, one can see including a history of head injuries, depression, or hypertension.

As per researchers, the said infrared sensor which can be used in the novel blood test, is analysing, if the biomarkers show already pathological changes, which can take place more than 15 years before any clinical symptoms appear.

Moreover, the researchers further clarified the fact which is connected with the major problem of the Alzheimer’s disease, and said that by the time the first clinical symptoms appear, it will be highly notable that the massive irreversible damage to the brain has already occurred. Thus, that time, the researchers, said the only option available will be the symptomatic treatment.

Further, Klaus Gerwert from the Ruhr- University Bochum in Germany, said that the blood tests, detecting Alzheimer’s in its pre- dementia stage is required, when anyone wishes to have a drug at disposal that can significantly inhibit the progress of the disease.

Also, while elaborating the research, the researchers further said that the secondary structure of so- called Amyloid beta peptides serves as biomarker, for the novel test. And such structure changes in Alzheimer’s patients.

Moreover, the infrared sensor extracts the Amyloid beta peptide from the body fluids. And researchers subsequently expanded the method towards blood analysis, after initially working with the cerebrospinal fluid. Thus, the research and its finding was found published in the journal biophotonics.

Related posts

Leave a Comment